SYNGR1 (Synaptogyrin 1) is a small transmembrane protein predominantly localized to synaptic vesicles in neuronal cells. It belongs to the synaptogyrin family, which includes SYNGR1. SYNGR2. SYNGR3. and SYNGR4. and is involved in regulating synaptic vesicle trafficking, neurotransmitter release, and synaptic plasticity. SYNGR1 plays a role in modulating intracellular calcium dynamics and interacts with other synaptic proteins like synaptophysin and synaptotagmin. Its expression is enriched in the central nervous system, particularly in regions associated with cognitive and motor functions, making it a focus in studies of neurological disorders.
SYNGR1 antibodies are essential tools for investigating the protein's expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study synaptic architecture and vesicle dynamics. Research has linked SYNGR1 dysregulation to neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, as well as neurodevelopmental disorders. Additionally, SYNGR1 has been implicated in cancer studies, where altered expression may influence tumor progression. These antibodies aid in identifying biomarkers and potential therapeutic targets, contributing to a deeper understanding of synaptic mechanisms and disease pathways. Validation of SYNGR1 antibodies for specificity and cross-reactivity is critical to ensure reliable experimental outcomes.